J&J CEO Gorsky Says Covid Shows Need for Global Health Security
(Bloomberg) -- There are lessons to be learned from the U.S. government's handling of the coronavirus pandemic, according to Johnson & Johnson Chief Executive Officer Alex Gorsky, who has steered the health-care behemoth as it pursues a vaccine to combat the disease.
President Donald Trump contracting Covid-19 “demonstrates that we're all vulnerable and we still all need to be very vigilant and diligent in the action we're taking to prevent this virus from spreading any further,” Gorsky said on Friday in an interview on The David Rubenstein Show: Peer-to-Peer Conversations on Bloomberg Television.
When asked by Carlyle Group Inc. co-founder Rubenstein if the White House and U.S. health agencies should have approached the pandemic differently, Gorsky said, “almost all of us have underestimated the dramatic impact of this outbreak.”
“But there are lessons to be learned,” Gorsky said. “Going forward, we're going to understand much better that if we don't have global public health security, we don't have national security, we don't have economic security and we will not have security of society.”
The U.S. government needs to shift away from “a maniacal focus on efficiency and effectiveness in certain cases to one more of resiliency and sustainability, particularly for these kinds of situations,” Gorsky added.
Earlier this month, Johnson & Johnson joined the short list of vaccine makers that have moved an experimental coronavirus shot into late-stage human studies in the U.S. The New Brunswick, New Jersey-based company has since begun dosing up to 60,000 volunteers, marking the first big trial of an Covid-19 inoculation that may work after just one shot.
Gorsky said the 60,000-person objective was determined in conjunction with U.S. regulators in hopes that it would serve as “robust a clinical development program as possible” that would produce “the confidence we need to demonstrate the safety and efficacy of our approach.”
Other front-runners such as Pfizer Inc. and partner BioNTech SE, Moderna Inc., and AstraZeneca Plc in conjunction with the University of Oxford, are further along in late-stage trials targeting tens of thousands of healthy participants. Pfizer has said it could determine whether its shot is safe and effective based on preliminary data before the end of October, while Moderna is aiming for the end of November. Their studies, which launched earlier in the summer, are seeking to enroll fewer patients than J&J's.
Urgent Question
Gorsky, who has been leading the 150,000-person health-care conglomerate remotely by Zoom, joked that he's asked “almost every 15 minutes” when a vaccine will be available.
“We would expect by late this year, early next year, we should be in a position to begin reviews with regulatory authorities to see if our vaccine is in fact safe, effective, and something that could be considered for an emergency use authorization,” Gorsky said, reaffirming J&J's previously-stated timeline.
An emergency use authorization would likely allow a limited supply of shots to go to specific at-risk populations, like health-care and essential workers. More broadly, Americans should expect to have access to a Covid-19 vaccine in late 2020 or early 2021, Gorsky said, noting that depend on the results of the late-stage studies from various vaccine candidates.
The pursuit of a vaccine has become a political topic, with some observers concerned that Trump's eagerness to see a vaccine authorized before the election could run counter to the science.
“This is an incredibly important time for the pharmaceutical industry,” Gorsky. “It's absolutely critical during a time when unfortunately, everything becomes politicized, that we rely on data, we rely on science, we rely on well-established regulatory guidelines to guide all of our decisions on the development and actual utilization of these vaccines.”
Gorsky, a graduate of U.S. Military Academy at West Point, has been at the helm of J&J for eight years. When asked by Rubenstein if he would consider taking on a role in the public sector, such as Secretary of Defense or Secretary of Health and Human Services, the 60-year-old Gorsky said: “I would always consider how to can you continue to serve other stakeholders, how can you continue to serve others, but I think I've got the best job in the world most days.”
©2020 Bloomberg L.P.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.